Finch Therapeutics Group (FNCHQ)
OTHER OTC:FNCHQ
Top Page
No summary available
Positive Factors
Unique Platform
The company's unique platform for microbiome therapy development provides a competitive advantage, potentially leading to innovative treatments and long-term growth opportunities.
Negative Factors
Persistent Losses
Ongoing financial losses and high leverage pose significant risks to Finch Therapeutics' sustainability, potentially limiting its ability to invest in growth and innovation.
Read all positive and negative factors
Positive Factors
Negative Factors
Unique Platform
The company's unique platform for microbiome therapy development provides a competitive advantage, potentially leading to innovative treatments and long-term growth opportunities.
Read all positive factors
Finch Therapeutics Group (FNCHQ) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$15.25M
Dividend YieldN/A
Average Volume (3M)6.04K
Price to Earnings (P/E)―
Beta (1Y)1.88
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees1
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,605,763
10 Day Avg. Volume2,609
30 Day Avg. Volume6,039
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.25
Price to Sales (P/S)54.13
P/FCF Ratio-0.18
Enterprise Value/Market Cap2.12
Enterprise Value/Revenue11.35
Enterprise Value/Gross Profit-176.51
Enterprise Value/Ebitda-1.66
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Finch Therapeutics Group Business Overview & Revenue Model
Company Description
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule...
How the Company Makes Money
Finch Therapeutics Group makes money primarily through the development and commercialization of microbiome therapies. The company's revenue streams include research and development collaborations, partnerships, and grants. These partnerships often...
Finch Therapeutics Group Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | TTM | Dec 2023 | Dec 2022 | Mar 2022 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.85M | 107.00K | 861.00K | 18.53M | 7.72M | 10.15M |
| Gross Profit | -183.00K | -1.41M | -4.65M | -38.75M | -25.43M | 9.84M |
| EBITDA | -19.51M | -32.48M | -82.69M | -57.68M | -38.65M | -20.66M |
| Net Income | -14.17M | -74.75M | -114.65M | -58.16M | -39.25M | -20.75M |
Balance Sheet | ||||||
| Total Assets | 45.58M | 55.37M | 162.94M | 225.37M | 165.34M | 103.57M |
| Cash, Cash Equivalents and Short-Term Investments | 16.04M | 25.12M | 71.04M | 133.48M | 99.71M | 42.19M |
| Total Debt | 28.99M | 30.13M | 52.34M | 6.01M | 1.81M | 143.15M |
| Total Liabilities | 31.36M | 32.49M | 67.23M | 23.14M | 261.06M | 163.10M |
| Stockholders Equity | 14.22M | 22.89M | 95.71M | 202.22M | -95.72M | -59.53M |
Cash Flow | ||||||
| Free Cash Flow | -18.04M | -31.50M | -77.03M | -83.12M | -33.96M | -18.32M |
| Operating Cash Flow | -18.05M | -31.50M | -74.85M | -67.13M | -31.33M | -17.32M |
| Investing Cash Flow | 71.00K | 1.33M | -2.18M | -15.92M | -2.63M | -973.00K |
| Financing Cash Flow | 0.00 | -16.16M | 14.87M | 119.11M | 91.47M | 53.30M |
Finch Therapeutics Group Technical Analysis
Negative
9.50
Price Trends
12.39
Negative
13.10
Negative
12.84
Negative
Market Momentum
-1.01
Positive
36.63
Neutral
74.41
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FNCHQ, the sentiment is Negative. The current price of 9.5 is below the 20-day moving average (MA) of 10.95, below the 50-day MA of 12.39, and below the 200-day MA of 12.84, indicating a bearish trend. The MACD of -1.01 indicates Positive momentum. The RSI at 36.63 is Neutral, neither overbought nor oversold. The STOCH value of 74.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FNCHQ.
Finch Therapeutics Group Risk Analysis
Finch Therapeutics Group disclosed 53 risk factors in its most recent earnings report. Finch Therapeutics Group reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Finch Therapeutics Group Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $15.25M | ― | ― | ― | ― | ― | |
46 Neutral | $2.96M | -0.38 | -489.66% | ― | 8.52% | 79.51% | |
46 Neutral | $12.38M | -1.17 | ― | ― | ― | 79.31% | |
44 Neutral | $6.78M | -0.34 | -253.43% | ― | ― | 94.52% | |
43 Neutral | $4.78M | -1.58 | -79.47% | ― | -99.97% | 35.59% | |
43 Neutral | $11.22M | -1.16 | -89.92% | ― | ― | 53.19% |
* Healthcare Sector Average
FNCHQ
Finch Therapeutics Group
9.50
-3.66
-27.81%
GOVX
GeoVax Labs
1.33
-22.47
-94.41%
MBRX
Moleculin Biotech
2.32
-17.38
-88.22%
PULM
Pulmatrix
1.31
-4.21
-76.27%
NCNA
Nucana
1.63
-148.37
-98.91%
CMMB
Chemomab Therapeutics
1.56
-2.52
-61.76%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―